Q1 2025 Omeros Corp Earnings Call Transcript
Key Points
- Omeros Corp (OMER) successfully completed a debt exchange, reducing its total debt by $10 million and lowering near-term repayment obligations by over $100 million.
- The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital.
- FDA has accepted the resubmitted Biologics License Application for narsoplimab, with a target action date set for September 25, indicating progress towards approval.
- Narsoplimab demonstrated a statistically significant threefold greater improvement in survival for TATMA patients, positioning it as a potential first approved treatment for this condition.
- Omeros Corp (OMER) is preparing for the commercial launch of narsoplimab, with a focused strategy targeting top transplant centers and engaging with payers to ensure market readiness.
- Omeros Corp (OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter.
- The company is suspending its expanded access program for narsoplimab, affecting TATMA patients who currently lack an approved treatment.
- Clinical development of zaltenibart for PNH is temporarily paused due to capital considerations, potentially delaying progress in this program.
- OMIDRIA royalties decreased significantly in the first quarter, impacting revenue from this asset.
- Interest expense increased in the first quarter, partly due to changes in the OMIDRIA royalty obligation and new convertible notes.
Good afternoon and welcome to today's earnings call for Omeros Corporation.
(Operator Instructions)
Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today.
I'll turn the call over to Jennifer Williams, Investor Relations for Omeros.
Good afternoon and thank you for joining the call today. I'd like to remind you that some of the statements that will be made on the call today will be forward-looking. These statements are based on management's beliefs and expectations as of today only and are subject to change.
All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special notes in the risk factor section regarding forward-looking statements, and the company's quarterly report on Form 10-q, which was filed today with the SEC, and the risk factor section of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
